Aquestive Therapeutics (AQST) Other Working Capital Changes (2020 - 2021)

Aquestive Therapeutics' Other Working Capital Changes history runs 10 years deep, the most recent figure standing at -$272000.0 for Q1 2026.

• On a quarterly basis, Other Working Capital Changes rose 35.7% year-over-year to -$272000.0 in Q1 2026; TTM through Mar 2026 was -$1.4 million, a 89.84% increase from a year earlier, with the FY2025 full-year figure at -$571000.0, up 95.55% from the prior year.
• Other Working Capital Changes advanced to $167000.0 in Q1 2021 per AQST's latest filing, from -$144000.0 in the prior quarter.
• Across five years, Other Working Capital Changes topped out at $167000.0 in Q1 2021 and bottomed at -$144000.0 in Q1 2020.
• The 5-year median for Other Working Capital Changes is -$272000.0 (2025), against an average of $668764.7.
• Across the five-year window, Other Working Capital Changes jumped 2616.64% in 2022 and slumped 1539.6% in 2024, its largest moves.
• Year by year, Other Working Capital Changes stood at $14.5 million in 2022, then sank by 110.13% to -$1.5 million in 2023, then soared by 82.28% to -$261000.0 in 2024, then retreated by 4.21% to -$272000.0 in 2025, then changed by 0.0% to -$272000.0 in 2026.
• Per Business Quant, the three latest AQST Other Working Capital Changes figures stand at -$272000.0 (Q1 2026), -$272000.0 (Q4 2025), and -$1.2 million (Q3 2025).